Heart Valve Devices – Market Insights – United States

The US heart valve device market will continue to experience rapid growth, largely driven by the adoption of THV devices. Clinical investigations continue to generate positive results and propel the THV device market forward. Furthermore, novel products and new device types will continue to emerge in the coming years and expand the existing patient population, generating continued growth in the heart valve device market.

This Medtech 360 Report provides comprehensive data and analysis on the state of the market for heart valve devices in the US from 2019 through 2032.

Clinical trial results play an important factor in the heart valve device market.

What segments have been the most impacted by clinical results?

What key players will have a first-mover advantage if they can secure positive clinical trial results?

What novel devices have been approved or failed to gain approval due to data from clinical trials?

Securing approval for additional indications is a key strategy in the THV device market.

What clinical trials are currently taking place that could expand the scope of eligible patients for TAVI?

Which THV device segments are being driven by the approval of additional indications?

Which competitors are capitalizing on approvals for extra indications to gain a competitive advantage?

The competitive landscape for the THV device market is evolving.

Which competitors have the most diverse portfolios in the heart valve device space?

What market dynamics will occur between TMVI and TMVR devices?

Which companies are poised to earn FDA approval for their THV devices first?

What impact will these devices have once approved?

Recent market developments and events have a significant impact on the heart valve device market.

What effect have mergers and acquisitions had on this market?

How will innovations currently being developed and evaluated in clinical trials affect changes in market share dynamics?

Table of contents

Heart Valve Devices - Market Insights - United States

Zsuzsa Lindenmaier

Zsuzsa Lindenmaier is a senior analyst on the Cardiovascular Medtech Insights team at Clarivate. Zsuzsa holds a Bachelor’s of Science in Neuroscience from the University of Florida and earned her PhD from the Department of Medical Biophysics at the University of Toronto.

Contact sales Login to access report

Back to all Medtech Insights reports